Ann-Charlotte Rosendahl (b. 1963) is a Board Director of Toleranzia since 2020. She works as CEO of Sobrera Pharma AB and has over 20 years of experience in the development, commercialization and launch of pharmaceuticals on the international scene from senior positions in MSD, AstraZeneca and Roche. Ann-Charlotte Rosendahl has lived and worked in the US and Switzerland for a number of years, and has been deeply engaged in strategic, business development and operational activities at several biotechnology companies, including at a Board of Directors level.

“Anders Milton has contributed greatly to Toleranzia’s development during his time as Chair of the Board, and I am honored to have been entrusted to take over this important role”, said Ann-Charlotte Rosendahl, incoming Chair of the Board at Toleranzia.
 
Anders Milton joined Toleranzia’s Board of Directors in 2018.
 
For further information, please contact:
Ann-Charlotte Rosendahl – Chair of the Board, Toleranzia
Phone: +46 (0)73 – 209 6405
E-mail: ann-charlotte.rosendahl@toleranzia.com
 
About Toleranzia
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08 503 015 50, CA@mangold.se, is the Company’s Certified Adviser.